Table 1 Sociodemographic and clinical characteristics of patients with metastatic genitourinary cancer (N = 60)
From: Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
Characteristics | N (%) |
|---|---|
Gender | |
Male | 41 (68.3) |
Female | 19 (31.7) |
Age | |
M (SD; min-max) | 65.1 (13.1; 31–91) |
Marital Status | |
Single | 3 (5.0) |
Married | 49 (81.7) |
Divorced | 3 (5.0) |
Widowed | 5 (8.3) |
Education | |
Elementary School | 4 (6.7) |
High School | 5 (8.3) |
Some College | 16 (26.7) |
College Degree | 23 (38.3) |
Beyond College | 12 (20.0) |
Race | |
White | 45 (75.0) |
Hispanic | 5 (8.3) |
Black | 2 (3.3) |
Japanese | 3 (5.0) |
Chinese | 2 (3.3) |
East Asian | 2 (3.3) |
South East Asian | 1 (1.7) |
Annual Income | |
Less than 40,000 | 4 (6.7) |
40,000 to 100,000 | 23 (38.3) |
More than 100,000 | 33 (55.0) |
Employment Status | |
More than 32 h | 6 (10.0) |
Less than 32 h | 6 (10.0) |
Unemployed | 1 (1.7) |
Homemaker | 2 (3.3) |
Disability | 16 (26.7) |
Retired | 29 (48.3) |
Cancer | |
Renal Cell Carcinoma | 38 (63.4) |
Urothelial Carcinoma | 17 (28.3) |
Prostate Cancer | 5 (8.3) |
Immunotherapy | |
Nivolumab | 21 (35.0) |
Atezolizumab | 18 (30.0) |
Nivolumab/Ipilimumab | 13 (21.7) |
Pembrolizumab | 6 (10.0) |
Avelumab | 2 (3.3) |
Line of Therapy | |
1st line | 20 (33.3) |
2nd line | 27 (45.0) |
3rd line | 6 (10.0) |
4th line | 4 (6.7) |
5th line | 3 (5.0) |